Contraceptive Preference Among Women at Risk of HIV Acquisition in a Preparatory Screening Study for a Phase III Microbicide Trial in South Western Uganda

AIDS Behav. 2018 Jul;22(Suppl 1):131-138. doi: 10.1007/s10461-018-2177-3.

Abstract

Contraceptive preferences of women at risk for HIV acquisition are not well documented. We report on contraceptive choices among women residing in small townships in southwestern Uganda. This was part of preparatory efforts for recruitment into the Ring Study, a phase 3 microbicide trial, between July 2013 and October 2014. Clinicians provided contraceptives per a woman's choice. HIV testing and screening for other sexually transmitted infections were done at first contact and at screening for the trial. Contraceptive choice was summarized by demographics and regression analysis to show factors associated with use of the injectable method. Of 6725 women contacted, 489 were prescreened. Of these 489 women, most (306, 63%) were already using contraception. Injectables were most preferred (58.7%), followed by implants (23.9%). Women living with a regular sexual partner preferred the injectable method (61.0%, P = 0.06), compared with other methods. Women at risk for HIV infection are willing to initiate use of modern contraceptives, which may reduce study dropout during intervention trials due to unintended pregnancy. Registration no: NCT01539226.

Keywords: Contraceptive preference; Contraceptives; Uganda; Women at high-risk.

MeSH terms

  • Adult
  • Anti-Infective Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic*
  • Contraception / methods*
  • Contraception / statistics & numerical data*
  • Contraceptive Agents, Female / administration & dosage*
  • Drug Implants
  • Female
  • HIV Infections / prevention & control
  • HIV Infections / transmission*
  • Humans
  • Injections
  • Patient Preference / statistics & numerical data*
  • Pregnancy
  • Uganda / epidemiology
  • Young Adult

Substances

  • Anti-Infective Agents
  • Contraceptive Agents, Female
  • Drug Implants

Associated data

  • ClinicalTrials.gov/NCT01539226